ISSN: 2321 – 0494


News Flash

NL-1-2014-LETTER-1 CELLS...

www.ijfstonline.org CELLS IN LIVING MICE 'REPROGRAMMED' TO EMBRYONIC-LIKE STATE S. Sharmilabanu.,(B.Pharm Final Year), Vels university. Stem cells Stem cells are undifferentiated biological...

Read more...

NL-1-2014-LETTER-2 -...

www.ijfstonline.org BETTER ACTION ON WARFARIN ON YOUNGER HEART FAILURE PATIENTS   By:  Dhulipala Sowmya.,(B-Pharm II year),Vels University Warfarin may be more beneficial than aspirin in...

Read more...

...

  www.ijfstonline.org EFFECTS OF POLLUTION ON HUMAN HEALTH By:Rohin kumar.,(B-Pharm I Year)Vels Uuniversity The overview of main health effects on humans from some common types of pollution....

Read more...

NL-1-2014-LETTER-4...

www.ijfstonline.org PROGERIA By:  Prithivi Logathasan,(B-Pharm III Year),Vels University HGPS (Hutchinson-Gilford Progeria Syndrome) or Progeria is an extremely rare, fatal genetic condition....

Read more...

NL-1-2014-LETTER-5...

www.ijfstonline.org OBESE MADE LEAN BY LEANS By:  S.Santhya.,(B-Pharm-Final Year)Vels University The Microbes from Lean People Act as Anti-Obesity Agents. Bugs that lurk in the guts of slim...

Read more...

User Login



I2OR index

Who's Online

We have 8 guests online
Home Newsletters NL-1-2014-LETTER-16-FDA APPROVES ZYKADIA (CERITINIB) FOR METASTATIC NON-SMALL CELL LUNG CANCER
NL-1-2014-LETTER-16-FDA APPROVES ZYKADIA (CERITINIB) FOR METASTATIC NON-SMALL CELL LUNG CANCER PDF Print E-mail

www.ijfstonline.org

FDA APPROVES ZYKADIA (CERITINIB) FOR METASTATIC NON-SMALL CELL LUNG CANCER

P.Maheshwari*, V.Ravichandiran, B.Senthilnathan

School of Pharmaceutical Sciences, Vels University, India

April 29, 2014 -- The U.S. Food and Drug Administration today granted accelerated approval to Zykadia (ceritinib) for patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC).

Zykadia is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor that blocks proteins that promote the development of cancerous cells. It is intended for patients with metastatic ALK-positive NSCLC who were previously treated with crizotinib, the only other approved ALK tyrosine kinase inhibitor.

Lung cancer is the leading cause of cancer-related deaths among men and women. According to the National Cancer Institute, an estimated 224,210 Americans will be diagnosed with lung cancer, and 159,260 will die from the disease this year. About 85 percent of lung cancers are NSCLC, making it the most common type of lung cancer. However, only 2-7 percent of patients with NSCLC are ALK-positive.

“Today’s approval illustrates how a greater understanding of the underlying molecular pathways of a disease can lead to the development of specific therapies aimed at these pathways,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “It also demonstrates the FDA’s commitment to working cooperatively with companies to expedite a drug’s development, review and approval, reflecting the promise of the breakthrough therapy designation program.”

Zykadia is the fourth drug with breakthrough therapy designation to receive FDA approval. It is being approved four months ahead of the product’s prescription drug user fee goal date of Aug. 24, 2014, the date the agency was scheduled to complete review of the drug application.

The FDA granted Zykadia breakthrough therapy designation, priority review and orphan product designation because the sponsor demonstrated through preliminary clinical evidence that the drug may offer a substantial improvement over available therapies; the drug had the potential, at the time of the application was submitted, to be a significant improvement in safety or effectiveness in the treatment of a serious condition; and the drug is intended to treat a rare disease, respectively.

The FDA is approving Zykadia under the agency’s accelerated approval program, which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients. This program provides earlier patient access to promising new drugs while the company conducts confirmatory clinical trials.

Zykadia’s safety and effectiveness were established in a clinical trial of 163 participants with metastatic ALK-positive NSCLC. All participants were treated with Zykadia. Results showed that about half of the participants had their tumors shrink, and this effect lasted an average of about seven months.

Common side effects of Zykadia include gastrointestinal symptoms such as diarrhea, nausea, vomiting and abdominal pain. Laboratory abnormalities such as increased liver enzymes, pancreatic enzymes and increased glucose levels were also observed.

References:

 

Zykadia (ceritinib) FDA Approval History

 

Latest News

Popular

Indexing

News Letter


© 2012 Internationaljournalofindiansciences.org. All Rights Reserved. Powered by JK Webdesigns.

Free Counters